134 related articles for article (PubMed ID: 20395318)
21. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
[TBL] [Abstract][Full Text] [Related]
22. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
[TBL] [Abstract][Full Text] [Related]
23. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Geist C; Dahlbom M; Silverman DH; Satyamurthy N; Phelps ME; Chen W
J Nucl Med; 2012 Jan; 53(1):29-36. PubMed ID: 22159180
[TBL] [Abstract][Full Text] [Related]
24. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
[TBL] [Abstract][Full Text] [Related]
25. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
van Waarde A; Cobben DC; Suurmeijer AJ; Maas B; Vaalburg W; de Vries EF; Jager PL; Hoekstra HJ; Elsinga PH
J Nucl Med; 2004 Apr; 45(4):695-700. PubMed ID: 15073267
[TBL] [Abstract][Full Text] [Related]
26. [Use of 11F-fluorothymidine positron emission tomography in brain tumor].
Kawai N; Kagawa M; Miyake K; Nishiyama Y; Yamamoto Y; Shiraishi H; Ichikawa T; Tamiya T
No Shinkei Geka; 2009 Jul; 37(7):657-64. PubMed ID: 19621774
[TBL] [Abstract][Full Text] [Related]
27. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.
Trigonis I; Koh PK; Taylor B; Tamal M; Ryder D; Earl M; Anton-Rodriguez J; Haslett K; Young H; Faivre-Finn C; Blackhall F; Jackson A; Asselin MC
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):682-93. PubMed ID: 24504503
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation.
Oyama N; Ponde DE; Dence C; Kim J; Tai YC; Welch MJ
J Nucl Med; 2004 Mar; 45(3):519-25. PubMed ID: 15001697
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma.
Backes H; Ullrich R; Neumaier B; Kracht L; Wienhard K; Jacobs AH
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1960-7. PubMed ID: 19672593
[TBL] [Abstract][Full Text] [Related]
30. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
31. Imaging regional variation of cellular proliferation in gliomas using 3'-deoxy-3'-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study.
Price SJ; Fryer TD; Cleij MC; Dean AF; Joseph J; Salvador R; Wang DD; Hutchinson PJ; Clark JC; Burnet NG; Pickard JD; Aigbirhio FI; Gillard JH
Clin Radiol; 2009 Jan; 64(1):52-63. PubMed ID: 19070698
[TBL] [Abstract][Full Text] [Related]
32. 3'-Deoxy-3'-[(18)F]-fluorothymidine ([(18)F]-FLT) transport in newly diagnosed glioma: correlation with nucleoside transporter expression, vascularization, and blood-brain barrier permeability.
Shinomiya A; Miyake K; Okada M; Nakamura T; Kawai N; Kushida Y; Haba R; Kudomi N; Tokuda M; Tamiya T
Brain Tumor Pathol; 2013 Oct; 30(4):215-23. PubMed ID: 23423309
[TBL] [Abstract][Full Text] [Related]
33. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
[TBL] [Abstract][Full Text] [Related]
34. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.
Spence AM; Muzi M; Link JM; O'Sullivan F; Eary JF; Hoffman JM; Shankar LK; Krohn KA
Mol Imaging Biol; 2009; 11(5):343-55. PubMed ID: 19326172
[TBL] [Abstract][Full Text] [Related]
35. Combining 3'-Deoxy-3'-[18F] fluorothymidine and MRI increases the sensitivity of glioma volume detection.
Fernandez P; Zanotti-Fregonara P; Eimer S; Gimbert E; Monteil P; Penchet G; Lamare F; Perez P; Vimont D; Ledure S; Tourdias T; Loiseau H
Nucl Med Commun; 2019 Oct; 40(10):1066-1071. PubMed ID: 31469809
[TBL] [Abstract][Full Text] [Related]
36. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
37. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ
J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614
[TBL] [Abstract][Full Text] [Related]
38. Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
Muzi M; Mankoff DA; Grierson JR; Wells JM; Vesselle H; Krohn KA
J Nucl Med; 2005 Feb; 46(2):371-80. PubMed ID: 15695799
[TBL] [Abstract][Full Text] [Related]
39. Reproducibility of the kinetic analysis of 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography in mouse tumor models.
Choi SJ; Kim SY; Kim SJ; Lee JS; Lee SJ; Park SA; Lee SJ; Yun SC; Im KC; Oh SJ; Kim SW; Kim JS; Ryu JS; Moon DH
Nucl Med Biol; 2009 Oct; 36(7):711-9. PubMed ID: 19720283
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas.
Shinomiya A; Kawai N; Okada M; Miyake K; Nakamura T; Kushida Y; Haba R; Kudomi N; Yamamoto Y; Tokuda M; Tamiya T
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):175-85. PubMed ID: 23229746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
